An assay is disclosed based on the successful transmission of DLB, and to a much lesser extent PD, to cultured HEK cells expressing the A53T and E46K point mutation. DLB prion activity was achieved by treatment of brain homogenates with detergent extraction and limited proteolysis followed by polyoxometalate precipitation of the prions. The results show the MSA strain of α-synuclein prions differs from those causing PD and DLB. Manipulating dominant negative inhibition of α-synuclein prions has created a new approach to identifying novel prions and deciphering the features of their multiplication.

An assay is disclosed based on the successful transmission of DLB, and to a much lesser extent PD, to cultured HEK cells expressing the A53T and E46K point mutation. DLB prion activity was achieved by treatment of brain homogenates with detergent extraction and limited proteolysis followed by polyoxometalate precipitation of the prions. The results show the MSA strain of α-synuclein prions differs from those causing PD and DLB. Manipulating dominant negative inhibition of α-synuclein prions has created a new approach to identifying novel prions and deciphering the features of their multiplication.

Various embodiments generally relate to intelligently designing aptameric peptides for binding with a specific receptor and forming aptameric peptide libraries with the designed peptides. The aptameric peptides libraries can be tissue-specific and be used in drug delivery and therapeutic applications, in which designed peptides can be implanted on exosome surfaces for exosomal cargo delivery to a specific tissue. Various embodiments of the present disclosure involve the use of a generative adversarial network (GAN) machine learning model configured (e.g., trained) and used to output designed peptides that are similar to pre-existing peptides of a peptide dataset but that specifically bind to a selected receptor and have various selected physiochemical properties. In various embodiments, GAN machine learning models may receive representations of the pre-existing peptides and may output representations of designed peptides according to peptide vectorization and encoding schemas based at least in part on the amino acids within a peptide.

Provided herein are polymeric α-hydroxy aldehyde or α-hydroxy ketone reagents which can be conjugated to amine-containing compounds to form stable conjugates in a single-step reaction. In selected embodiments, the polymeric reagent itself incorporates an internal proton-abstracting (basic) functional group, to promote more efficient reaction. The substituent is appropriately situated, via a linker if necessary, to position the group for proton abstraction, preferably providing a 4- or 5-bond spacing between the abstracting atom and the hydrogen atom on the α-carbon. Also provided are methods of using the reagents and stable, solubilized conjugates of the reagents with biologically active compounds. In preferred embodiments, the polymeric component of the reagent or conjugate is a polyethylene glycol.

Provided herein are recombinant poxviruses that are stable through successive passaging of the recombinant poxviruses. More particularly, the recombinant poxviruses comprise one or more modified nucleic acids encoding MUC1, CEA, and/or TRICOM antigens, wherein the recombinant poxviruses are stable through successive passaging. Also, provided herein are compositions and method related thereto.

An objective of the present invention is to provide novel means that allow reducing the rate of mistranslation into unintended amino acids due to misreading of codons. In a number of embodiments, the present disclosure provides compositions for translation which contain a tRNA having a specific combination of bases at positions 32, 33, 37, and 38 (tRNA numbering rule) in the tRNA. According to a specific embodiment of the present disclosure, the rate of introduction of unintended amino acids due to codon misreading can be reduced.

An objective of the present invention is to provide novel means that allow reducing the rate of mistranslation into unintended amino acids due to misreading of codons. In a number of embodiments, the present disclosure provides compositions for translation which contain a tRNA having a specific combination of bases at positions 32, 33, 37, and 38 (tRNA numbering rule) in the tRNA. According to a specific embodiment of the present disclosure, the rate of introduction of unintended amino acids due to codon misreading can be reduced.

The present invention provides novel methods for poling piezoelectric materials, e.g., collagen, which are carried out in the absence of liquid media and at a relatively low temperature. The present invention also provides electroactive scaffolds comprising poled collagen for promoting cell growth and differentiation.

The present invention provides novel methods for poling piezoelectric materials, e.g., collagen, which are carried out in the absence of liquid media and at a relatively low temperature. The present invention also provides electroactive scaffolds comprising poled collagen for promoting cell growth and differentiation.

TCR The present invention relates to an engineered T cell receptor (TCR). In particular, the present invention relates to methods for expression of a TCR when expressed as an exogenous TCR, to methods for selecting a TCR with high cell surface expression when expressed as an exogenous TCR and to methods for identifying residues which contribute to the cell surface expression level of a TCR. The present invention also relates to an engineered TCR which has a high level of cell surface expression when expressed as an exogenous TCR compared to the corresponding germline TCR sequence.